文献速递中枢神经肿瘤放疗放疗物理与技术

商用深度学习软件生成脑部合成CT的临床验证

Clinical validation of a commercially available deep learning software for synthetic CT generation for brain.
PubMed 文献 · Radiat Oncol · 2021-04-07

本研究前瞻性纳入20例脑部恶性肿瘤患者(其中14例有术后颅骨切除区),验证基于卷积神经网络(CNN)的商用软件MRI Planner生成合成CT(sCT)用于MRI-only放疗计划的可行性。结果显示sCT与CT在剂量学和几何学评估上相当,术后骨切除区显示准确,患者摆位验证中CBCT-sCT与CBCT-CT配准无临床相关偏差,表明该软件可用于脑肿瘤放疗计划。

要点

  • 商用CNN软件生成的sCT在剂量学参数上平均差异低于0.2%。
  • sCT体轮廓内平均绝对误差为62.2±4.1 HU。
  • 术后骨切除区在sCT上显示准确,CBCT配准无临床相关偏差。

核心结论

  • 商用CNN软件MRI Planner生成的sCT在剂量学和几何学评估上与CT相当,可用于脑肿瘤放疗计划。

研究设计与样本

  • 前瞻性研究纳入20例脑部恶性肿瘤患者,其中14例有术后颅骨切除区。
  • 在临床脑部MR协议中加入Dixon序列用于sCT生成,由软件MRI Planner提供sCT图像。
  • 治疗计划在CT上优化并在sCT上重算,评估剂量学和几何学终点,并对术后病例进行额外分析。
  • 通过将锥形束CT(CBCT)分别与sCT和CT刚性配准评估患者摆位验证的临床稳健性。

主要发现

  • 所有sCT图像成功生成,术后骨切除区显示准确。
  • 所有患者sCT体轮廓内平均绝对误差为62.2±4.1 HU。
  • 靶区和危及器官评估参数的平均吸收剂量差异低于0.2%。
  • 全局伽马(1%/1 mm)平均通过率在PTV内为100.0±0.0%,全剂量分布为99.1±0.6%。
  • CBCT-sCT与CBCT-CT图像配准未发现临床相关偏差;Dixon图像体素级几何畸变均值在软组织中低于0.1 mm,在空气和骨骼中低于0.2 mm。

关键数值与推荐

  • sCT体轮廓内平均绝对误差为62.2±4.1 HU。
  • 靶区和危及器官参数的平均吸收剂量差异低于0.2%。
  • 全局伽马(1%/1 mm)平均通过率在PTV内为100.0±0.0%,全剂量分布为99.1±0.6%。
  • Dixon图像体素级几何畸变均值在软组织中低于0.1 mm,在空气和骨骼中低于0.2 mm。

临床怎么用

  • MRI Planner生成的sCT可用于脑肿瘤MRI-only放疗计划,包括术后骨切除患者。
  • CBCT与sCT配准可用于患者摆位验证,无临床相关偏差。

局限性

  • 研究样本量较小(20例),为前瞻性单中心验证。
  • 未报告长期临床随访或更大规模的多中心验证结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most studies on synthetic computed tomography (sCT) generation for brain rely on in-house developed methods. They often focus on performance rather than clinical feasibility. Therefore, the aim of this work was to validate sCT images generated using a commercially available software, based on a convolutional neural network (CNN) algorithm, to enable MRI-only treatment planning for the brain in a clinical setting. METHODS: This prospective study included 20 patients with brain malignancies of which 14 had areas of resected skull bone due to surgery. A Dixon magnetic resonance (MR) acquisition sequence for sCT generation was added to the clinical brain MR-protocol. The corresponding sCT images were provided by the software MRI Planner (Spectronic Medical AB, Sweden). sCT images were rigidly registered and resampled to CT for each patient. Treatment plans were optimized on CT and recalculated on sCT images for evaluation of dosimetric and geometric endpoints. Further analysis was also performed for the post-surgical cases. Clinical robustness in patient setup verification was assessed by rigidly registering cone beam CT (CBCT) to sCT and CT images, respectively. RESULTS: All sCT images were successfully generated. Areas of bone resection due to surgery were accurately depicted. Mean absolute error of the sCT images within the body contour for all patients was 62.2 ± 4.1 HU. Average absorbed dose differences were below 0.2% for parameters evaluated for both targets and organs at risk. Mean pass rate of global gamma (1%/1 mm) for all patients was 100.0 ± 0.0% within PTV and 99.1 ± 0.6% for the full dose distribution. No clinically relevant deviations were found in the CBCT-sCT vs CBCT-CT image registrations. In addition, mean values of voxel-wise patient specific geometric distortion in the Dixon images for sCT generation were below 0.1 mm for soft tissue, and below 0.2 mm for air and bone. CONCLUSIONS: This work successfully validated a commercially available CNN-based software for sCT generation. Results were comparable for sCT and CT images in both dosimetric and geometric evaluation, for both patients with and without anatomical anomalies. Thus, MRI Planner is feasible to use for radiotherapy treatment planning of brain tumours.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lerner M, Medin J, Jamtheim Gustafsson C, et al. Clinical validation of a commercially available deep learning software for synthetic CT generation for brain. Radiat Oncol. 2021. PMID: 33827619. doi:10.1186/s13014-021-01794-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。